↑ parent cluster · ·
research dossier →

Creative Testing Solutions

TEMPE, AZ · EIN 271120123 · Form 990 · FY2022 · NTEE M99 · Public Safety & Disaster Relief · Very Large (>$50M) · www.mycts.org
revenue
$438.8M
expenses
$396.7M
net assets
$114.8M
employees
958
volunteers
11
program ratio
94%
filing since
2020
mission · from form 990

TO PROVIDE EXCEPTIONAL CUSTOMIZED LABORATORY TESTING SERVICES TO SUPPORT THE HOSPITALS AND OTHER HEALTHCARE ORGANIZATIONS WITH THEIR LIFE SAVING MISSIONS.

profile · synthesized from sources

Creative Testing Solutions is a nonprofit organization that operates laboratories for infectious disease testing of blood and plasma donations. It serves healthcare partners by ensuring the safety of blood and plasma-derived products for transfusion and therapeutic use. CTS also conducts research and development in transfusion medicine and cellular therapies.

irs program accomplishments · form 990 part iii · fy2022

what they reported doing

Program narrative the organization filed with the IRS. Ordered by program spending.

  1. #1 primary $2.29M
    RESEARCH AND DEVELOPMENT THE CTS RESEARCH PROGRAM IS DEDICATED TO ADVANCING BLOOD SAFETY AND EVIDENCE-BASED TRANSFUSION PRACTICES THROUGH SCEINTIFIC RESEARCH. THE CTS RESEARCH PROGRAM FOCUSES ON THE DEVELOPMENT AND/OR EVALUATION OF NEW BLOOD DONOR SCREENING TECHNOLOGIES WHICH SIGNIFICANTLY IMPROVE AND PROMOTE BLOOD SAFETY IN THE AREAS OF INFECTIOUS DISEASE, IMMUNOLOGY, MOLECULAR DIAGNOSTICS, AND EPIDEMIOLOGY. ADDITIONALLY, THE CTS RESEARCH PROGRAM SERVES AS THE FOCUS FOR A MULTI-INSTITUTIONAL CONSORTIUM WHICH COLLECTS AND INTEGRATES TESTING DATA FROM APPROXIMATELY 75% OF THE US BLOOD SUPPLY FOR THE PURPOSE OF NATIONAL HAEMOVIGILANCE, HORIZON SCANNING FOR EMERGING INFECTIOUS DISEASES RELEVANT TO BLOOD SAFETY, AND PROVIDING CRITICAL INFORMATION FOR THE EVALUATION OF BEST PRACTICES IN TRANSFUSION MEDICINE, THE PROMOTION OF DONOR HEALTH, AND THE IMPROVEMENT OF TRANSFUSION RECIPIENT OUTCOMES.
named programs · 7 · from sources

what they call their work

Blood Donor Testing
High-volume laboratory testing of blood donations for infectious disease markers and screening tests required by FDA and other regulatory bodies
Blood Donor Testing Services
Provides infectious disease marker and screening tests for blood donations using FDA licensed test kits and reagents, ensuring the safety of the blood supply.
CTS Research Consortium
Collaborative research initiative with Vitalant Research Institute, Carter BloodCare, OneBlood, ITxM, New York Blood Center, and Bloodworks Northwest
Plasma Testing
Full spectrum testing for source plasma and recovered plasma partners, including NAT, viral marker, and ancillary testing
Plasma Testing Services
Offers comprehensive testing profiles for source plasma and recovered plasma, including NAT, viral marker, and ancillary testing.
Research & Development
Supports clinical trials and research studies in transfusion medicine and cellular therapies; collaborates with healthcare partners and research institutions
Special Testing Laboratory
Phoenix-based lab performing confirmatory, supplemental, and non-donation testing including for eye, tissue, organ, cord blood, and pediatric stem cell donors
activities · 34

what they do

direct service · 20
  • Conduct specialized donor testing in Phoenix laboratory Infectious Disease Screening for Blood and Plasma Donors
    Maintains a dedicated research and special testing laboratory in Phoenix that performs confirmatory, supplemental, donor re-entry, and follow-up testing, including specialized assays for HAV, Parvo B19, Babesia, and Zika under investigational and licensed settings.
  • Conduct specialized donor testing services Infectious Disease Screening for Blood and Plasma Donors
    Operates a specialized laboratory in Phoenix for confirmatory, supplemental, donor re-entry, and follow-up testing, including HAV and Parvo B19 testing. Also performs testing for eye, tissue, organ, pediatric stem cell, cord blood, and cellular therapy donations with limited sample volumes.
  • Ensure regulatory compliance and laboratory accreditation Infectious Disease Screening for Blood and Plasma Donors
    Maintains FDA registration and current CLIA certification for all laboratories, with additional accreditations from AABB, EU, and multiple state licenses, ensuring adherence to national and international standards.
  • Expansion and transition of pathogen testing programs Infectious Disease Screening for Blood and Plasma Donors
    Transitioned all six laboratories to licensed Zika testing and all five to licensed pooled Babesia testing, and implemented investigational Dengue and Babesia microti antibody testing in response to partner needs and endemic threats.
  • High-Volume Donor Testing Laboratory Operations Infectious Disease Screening for Blood and Plasma Donors
    Operates multiple high-volume donor testing laboratories across the United States, located near major metropolitan airports, to screen blood and plasma donations for infectious disease markers and other required tests. These laboratories maintain FDA registration and current certifications including CLIA, AABB, and EU, and process millions of samples annually.
  • Implementation of New Testing Platforms and Assays Infectious Disease Screening for Blood and Plasma Donors
    Implements and transitions to new testing platforms and assays for various infectious diseases, including Ortho VIP viral marker testing, licensed pooled Babesia testing, licensed Zika testing, COVID-19 screening for convalescent plasma, and Dengue testing.
  • Implementation of advanced diagnostic testing platforms Infectious Disease Screening for Blood and Plasma Donors
    Implements and transitions to advanced diagnostic platforms including the Ortho VIP and VITROS® systems for viral marker and COVID-19 screening, and has converted assays across multiple laboratories to improve efficiency and support convalescent plasma programs.
  • Launch and scale source plasma testing services Infectious Disease Screening for Blood and Plasma Donors
    Launched source plasma testing as a new business line, providing NAT, viral marker, and ancillary testing services for major plasma fractionators, including processing 4.9 million plasma samples in 2016.
  • Maintain regulatory compliance and laboratory certifications Infectious Disease Screening for Blood and Plasma Donors
    All laboratories maintain FDA registration and current CLIA certification, with additional accreditations from AABB, EU, and multiple state licenses, ensuring compliance with national and international standards for donor testing.
  • Operate high-volume donor testing laboratories Infectious Disease Screening for Blood and Plasma Donors
    Operates six high-volume donor testing laboratories in Charlotte, Dallas, Phoenix, St. Louis, Tampa, San Marcos, Austin, and Memphis, located near major metropolitan airports, providing FDA-compliant infectious disease screening for blood and plasma donations. These facilities serve as core testing hubs for national blood and plasma donation programs.
  • Operate high-volume donor testing laboratories Infectious Disease Screening for Blood and Plasma Donors
    Operates six high-volume donor testing laboratories in Charlotte, Dallas, Phoenix, St. Louis, Tampa, and Memphis, with facilities strategically located near major metropolitan airports to support rapid sample processing. These laboratories conduct routine infectious disease screening for blood and plasma donors as required by the FDA and other regulatory bodies.
  • Operation of high-volume donor testing laboratories Infectious Disease Screening for Blood and Plasma Donors
    Operates six high-volume donor testing laboratories in Charlotte, Dallas, Phoenix, St. Louis, Tampa, San Marcos, Austin, and Memphis, located near major metropolitan airports, providing FDA-compliant infectious disease screening for blood, plasma, and other donations. These facilities serve as core testing hubs for national blood and plasma donation programs.
  • Plasma Testing Services Infectious Disease Screening for Blood and Plasma Donors
    Provides comprehensive testing services for source plasma and recovered plasma partners, including 5 NAT, viral marker, and ancillary testing, and has launched source plasma testing as a new business line.
  • Provide comprehensive infectious disease testing for blood and plasma Infectious Disease Screening for Blood and Plasma Donors
    Conducts routine and licensed screening for infectious disease markers—including NAT, viral markers, Zika, Babesia, and Dengue—on blood and source plasma donations in compliance with FDA and regulatory requirements. Implemented universal Zika testing and transitioned to licensed pooled Babesia and individual Zika testing across all laboratories.
  • Provide comprehensive infectious disease testing for diverse donor types Infectious Disease Screening for Blood and Plasma Donors
    Performs FDA-mandated screening for blood, plasma, tissue, eye, organ, cord blood, and cellular therapy donors, including testing for viral markers (NAT, antibody), Dengue, Zika, and Babesia microti, supporting both routine donor safety and convalescent plasma initiatives.
  • Regulatory-compliant infectious disease screening Infectious Disease Screening for Blood and Plasma Donors
    Performs FDA-mandated infectious disease marker screening for blood and plasma donations across all laboratories, maintaining FDA registration, CLIA certification, AABB accreditation, EU compliance, and multiple state licenses to ensure regulatory adherence.
  • Source and recovered plasma testing services Infectious Disease Screening for Blood and Plasma Donors
    Provides comprehensive testing for source plasma and recovered plasma partners, including nucleic acid testing (NAT), viral marker screening, and ancillary tests, supporting one of the largest plasma fractionators in the industry.
  • Specialized Donor Testing
    Conducts specialized testing for eye, tissue, and organ donors, as well as pediatric stem cell collections, cord blood, and other cellular therapy donations. This includes confirmatory, supplemental, donor re-entry, and donor follow-up testing, often with limited sample volumes.
  • Specialty testing for tissue, organ, and cellular therapy donors
    Conducts specialized testing for eye, tissue, organ, pediatric stem cell, cord blood, and other cellular therapy donations through a dedicated laboratory department in Phoenix, including confirmatory, supplemental, donor re-entry, and follow-up testing, particularly for low-volume samples.
  • Support convalescent plasma and pandemic response testing
    Implemented Ortho VITROS® platform in Tampa to screen blood donors for COVID-19 antibodies, supporting identification of convalescent plasma units. Contributed to research on SARS-CoV-2 antibody dynamics to inform convalescent plasma use during the pandemic.
research · 7
  • Conduct and support infectious disease research Transfusion Medicine & Cellular Therapy Research Support
    Participates in clinical trials and research studies in transfusion medicine and cellular therapies, supports research through sample provision and innovative testing via a Phoenix-based R&D department, and contributes data on blood safety related to donor deferral policies such as those for men who have sex with men (MSM).
  • Lead collaborative research initiatives Transfusion Medicine & Cellular Therapy Research Support
    Established the CTS Research Consortium with multiple blood centers to support infectious disease research and generate data for hypothesis-driven studies, contributing to six research publications in 2025.
  • Publication and dissemination of research findings Transfusion Medicine & Cellular Therapy Research Support
    Contributed to six research publications in 2025, including peer-reviewed work on spike and nucleocapsid antibody responses following SARS-CoV-2 infection and vaccination, supporting convalescent plasma research.
  • Research Consortium Management Transfusion Medicine & Cellular Therapy Research Support
    Established and manages the CTS Research Consortium with multiple blood centers to support infectious disease research and generate data for future hypothesis-based studies.
  • Research and Development Transfusion Medicine & Cellular Therapy Research Support
    Conducts and supports research in transfusion medicine and cellular therapies, including contributing to publications, participating in clinical trials, providing critical data on blood supply safety, and operating a Phoenix-based research and development department.
  • Research support and data generation in transfusion medicine Transfusion Medicine & Cellular Therapy Research Support
    Supports clinical trials and research in transfusion medicine and cellular therapies through sample provision, innovative testing, and data generation, including contributions to studies on SARS-CoV-2 antibody dynamics and infectious disease surveillance.
  • Support infectious disease and transfusion medicine research Transfusion Medicine & Cellular Therapy Research Support
    Contributes to peer-reviewed research, participates in clinical trials, and supports hypothesis-driven studies through data generation and sample provision, including research on SARS-CoV-2 antibody dynamics and donor deferral policy impacts on blood safety.
capacity building · 7
  • Deploy integrated laboratory information systems Laboratory Integration and Testing Modernization
    Implemented a unified laboratory information system across all six CTS laboratories as part of a Business Continuity Plan, improving data integration, operational resilience, and service reliability.
  • Expand and integrate laboratory operations through partnerships and mergers Laboratory Integration and Testing Modernization
    Assumed operational responsibility for Grifols’ three testing facilities in 2022 and merged with three Red Cross laboratories, expanding national testing capacity and integrating new sites into the CTS network.
  • Implement and optimize laboratory testing platforms Laboratory Integration and Testing Modernization
    Transitioned all laboratories to advanced testing platforms, including the Ortho VIP and VITROS® systems, and completed viral marker assay conversions in Dallas, Phoenix, and Tampa, achieving operational efficiency and cost savings for healthcare partners.
  • Implement and scale advanced laboratory testing platforms Infectious Disease Screening for Blood and Plasma Donors
    Deploys and transitions to advanced diagnostic platforms such as Ortho VIP and VITROS® across all laboratories, achieving regulatory compliance, cost savings, and improved testing capacity for infectious diseases including Zika, Babesia, and SARS-CoV-2.
  • Implement unified laboratory information systems Laboratory Integration and Testing Modernization
    Deployed a standardized laboratory information system across all six CTS laboratories as part of a Business Continuity Plan to enhance data integrity, interoperability, and operational resilience.
  • Laboratory System Integration and Expansion Laboratory Integration and Testing Modernization
    Implements unified laboratory information systems, merges with other testing laboratories to expand operations, and completes viral marker assay conversions to achieve cost savings for healthcare partners.
  • Laboratory systems integration and operational capacity building Laboratory Integration and Testing Modernization
    Enhanced operational resilience and efficiency by implementing a unified laboratory information system across all six laboratories and completing the integration of three former Red Cross testing facilities into CTS operations.
strategies · 44

how they think

Theories of action extracted from this org's own source material. Click any approach shared with other orgs to see the full field.

  • Advanced laboratory processing with regulatory compliance advanced laboratory processing unique to this org
    CTS uses state-of-the-art technology and FDA-licensed test kits and reagents to ensure accurate, compliant, and reliable blood specimen processing.
  • Advanced laboratory processing with regulatory compliance advanced laboratory processing unique to this org
    Utilizes state-of-the-art technology and FDA-licensed test kits and reagents to ensure accurate, reliable, and compliant processing of blood specimens, supporting high-stakes clinical decisions.
  • Advanced laboratory processing with regulatory compliance advanced laboratory processing unique to this org
    CTS ensures testing accuracy and reliability by using state-of-the-art technology and FDA-licensed test kits and reagents in its laboratory operations.
  • Advanced laboratory processing with regulatory compliance advanced laboratory processing unique to this org
    CTS uses state-of-the-art technology and FDA-licensed test kits and reagents to ensure accurate and compliant processing of blood specimens, supporting high reliability in testing outcomes.
  • Big data and collaborative research partnerships big_data_in_transfusion_medicine unique to this org
    CTS improves transfusion medicine by contributing to large-scale data initiatives and collaborating on research studies with healthcare partners, enhancing evidence-based practices and innovation.
  • Big data contribution to improve donor and recipient outcomes big_data_in_transfusion_medicine unique to this org
    CTS improves population-level health in transfusion medicine by contributing to large-scale, high-quality data initiatives that inform best practices and safety protocols.
  • Big data initiatives to improve donor and recipient health big_data_in_transfusion_medicine unique to this org
    Contributes to large-scale, high-quality data projects in transfusion medicine to generate insights that enhance the safety and efficacy of blood and biologic products for donors and recipients.
  • Blood safety research for global supply protection blood_safety_research unique to this org
    Conducts ongoing research to identify and monitor emerging and persistent safety threats in blood and biologics, ensuring the integrity and safety of the global blood and plasma supply chain.
  • Centralized laboratory operations for reliability centralized_laboratory_operations unique to this org
    CTS ensures consistent, safe, and efficient testing results through a centralized operational model that integrates laboratories and support teams under unified execution standards.
  • Centralized laboratory operations for reliability centralized_laboratory_operations unique to this org
    CTS ensures consistent, safe, and efficient testing delivery through a centralized operational model that coordinates laboratories and support teams under unified standards.
  • Centralized laboratory operations for reliability centralized_laboratory_operations unique to this org
    Ensures consistent, safe, and efficient testing outcomes through a centralized operational model that coordinates laboratories and support teams under unified standards and execution protocols.
  • Centralized, operationally excellent laboratory operations centralized_laboratory_operations unique to this org
    CTS ensures reliable, safe, and efficient testing through centralized operations and a company-wide operational excellence initiative focused on service quality, timeliness, and continuous improvement.
  • Collaborative research model to advance medical science collaborative_research_model unique to this org
    Partners with healthcare organizations and leads independent clinical trials and research studies to expand knowledge in transfusion medicine and cellular therapies, driving field-wide innovation.
  • Collaborative research model with healthcare partners collaborative_research_model unique to this org
    CTS co-develops knowledge and testing innovations by participating in clinical trials and research studies initiated by CTS or external healthcare collaborators.
  • Comprehensive quality control for testing accuracy comprehensive quality control unique to this org
    Ensures testing precision and reliability through internal quality control programs and participation in external quality assessment initiatives, maintaining high standards in diagnostic outcomes.
  • Comprehensive quality control for testing accuracy comprehensive quality control unique to this org
    CTS ensures high testing accuracy through internal quality control programs and participation in external quality assessment programs, maintaining reliability across its laboratory network.
  • Comprehensive quality control system comprehensive_quality_control unique to this org
    CTS maintains high testing accuracy by implementing internal quality control programs and participating in external quality assessment initiatives to validate performance across laboratories.
  • Comprehensive quality control system comprehensive quality control unique to this org
    To ensure testing accuracy, CTS implements internal quality controls and participates in external quality assessment programs, maintaining high standards across its laboratory network.
  • Customized laboratory testing for healthcare partners customized laboratory testing unique to this org
    CTS supports life-saving missions by providing tailored laboratory testing services that meet the specific needs of healthcare and research partners.
  • Customized laboratory testing for healthcare partners customized laboratory testing unique to this org
    Provides tailored testing solutions to meet the unique needs of healthcare partners, supporting their life-saving missions with flexible, mission-aligned laboratory services.
  • Customized, high-quality laboratory testing services customized laboratory testing unique to this org
    CTS provides tailored laboratory testing solutions to support healthcare partners’ unique needs, setting industry standards through innovation, service customization, and research integration.
  • Customized, high-standard laboratory services customized laboratory testing, innovation-driven laboratory standards unique to this org
    CTS differentiates its services by offering customized testing solutions for healthcare partners, setting industry standards through innovation, service customization, and research support.
  • Innovation-driven standards in laboratory testing innovation-driven laboratory standards unique to this org
    Establishes industry benchmarks in laboratory testing by combining innovation, customized service, rigorous quality standards, and research support to lead the field.
  • Innovation-driven standards in laboratory testing innovation-driven laboratory standards unique to this org
    CTS sets industry benchmarks by combining innovation, high-quality standards, customized service, and research support to define best practices in laboratory testing.
  • Learning organization model for continuous improvement learning organization model unique to this org
    CTS fosters innovation and operational improvements by systematically listening to clients and staff, integrating feedback into service and process enhancements.
  • Learning organization model for continuous improvement learning organization model unique to this org
    Fosters a culture of listening to clients and staff to identify improvement opportunities, driving innovation and adaptation across operations and services.
  • Learning organization model for continuous innovation learning organization model unique to this org
    CTS fosters a culture of listening to clients and staff to drive innovation, adapt services, and improve operations continuously.
  • Learning organization with operational excellence learning organization model, operational_excellence_initiative unique to this org
    CTS fosters continuous improvement by operating as a learning organization that listens to clients and staff, supported by a company-wide operational excellence initiative to enhance efficiency, reliability, and timeliness of testing services.
  • Multi-organizational governance for blood safety multi-organizational_governance unique to this org
    Creative Testing Solutions leverages a governing board composed of senior leaders from major blood organizations (American Red Cross, OneBlood, Vitalant) to align strategic direction with industry needs and ensure accountability in blood and plasma safety.
  • Multi-organizational governance for blood safety multi-organizational_governance unique to this org
    Creative Testing Solutions leverages a governing board composed of senior leaders from major blood organizations (American Red Cross, OneBlood, Vitalant) to ensure strategic alignment and oversight in support of national blood and plasma safety.
  • Multi-organizational governance for strategic oversight multi-organizational_governance unique to this org
    Governing board composed of senior executives and board members from three major blood service organizations (American Red Cross, OneBlood, and Vitalant) ensures strategic alignment, shared expertise, and sector-specific governance in service delivery and innovation.
  • Operational excellence initiative for service efficiency operational_excellence_initiative unique to this org
    CTS improves timeliness, service delivery, and operational efficiency through a company-wide initiative focused on continuous process improvement.
  • Operational excellence initiative for service improvement operational_excellence_initiative unique to this org
    Implements a company-wide program focused on enhancing service delivery, accelerating test reporting, and increasing operational efficiency across all functions.
  • Research-driven innovation in transfusion medicine clinical_and_experimental_therapy_development, big_data_in_transfusion_medicine, collaborative_research_model, blood_safety_research unique to this org
    CTS advances transfusion medicine and cellular therapies through internal R&D, blood safety research, participation in clinical trials, and contributions to large-scale data initiatives that improve donor and recipient health.
  • Research-driven innovation in transfusion medicine clinical_and_experimental_therapy_development unique to this org
    CTS advances clinical and experimental therapies through internal R&D, blood safety research, and participation in clinical trials, contributing to scientific knowledge and improved donor and recipient outcomes.
  • Research-driven innovation in transfusion medicine clinical_and_experimental_therapy_development unique to this org
    CTS advances clinical and experimental therapies through internal R&D, contributing to blood safety, emerging pathogen monitoring, and the development of new testing standards.
  • Research-driven innovation in transfusion medicine clinical_and_experimental_therapy_development unique to this org
    Advances clinical and experimental therapies through internal R&D, contributing to scientific knowledge and the development of safer, more effective transfusion and cellular therapy practices.
  • Specialized plasma testing network specialized_plasma_testing_network unique to this org
    CTS operates a dedicated network of high-volume and specialized laboratories to conduct targeted testing for pathogens like HAV and Parvo B19, meeting the specific requirements of plasma fractionators.
  • Specialized plasma testing network for fractionator needs specialized_plasma_testing_network unique to this org
    Operates a dedicated network of high-volume and specialized laboratories to conduct targeted testing for pathogens like HAV and Parvo B19, meeting the specific requirements of plasma fractionators.
  • Specialized plasma testing network with fractionator support specialized_plasma_testing_network unique to this org
    CTS operates a dedicated network of high-volume and specialized laboratories that conduct targeted testing (e.g., for HAV and Parvo B19) required by plasma fractionators, ensuring suitability for downstream therapeutic use.
  • Specialized plasma testing network with strategic logistics specialized_plasma_testing_network, strategic_geographic_placement unique to this org
    CTS operates a network of high-volume and specialized laboratories that conduct targeted testing for pathogens like HAV and Parvo B19, with facilities strategically located near major airports to enable rapid sample transport and efficient service delivery.
  • Strategic geographic placement for logistics efficiency strategic_geographic_placement unique to this org
    Locates laboratories near major metropolitan airports to enable rapid transport of samples, reducing turnaround time and enhancing the efficiency of plasma testing services.
  • Strategic geographic placement for logistics efficiency strategic_geographic_placement unique to this org
    Laboratories are located near major metropolitan airports to enable rapid transport of samples, reducing turnaround time and supporting timely plasma testing services.
  • Strategic geographic placement for logistics efficiency strategic_geographic_placement unique to this org
    Laboratories are located near major metropolitan airports to enable rapid transport of plasma samples, supporting time-sensitive testing and efficient national logistics.
financials · form 990 · fy2022

the money

revenue
Total revenue$438.77M
Contributions & grants$00%
Program service revenue$436.45M99%
Investment income$2.33M1%
Other revenue$0
expenses
Total expenses$396.70M
Program expenses94%
Admin / overhead6%
Fundraising0%
Salaries & benefits$87.18M
Grants paid out$0
Largest expense lineCompensation
balance sheet
Total assets$202.65M
Cash$22.83M
Investments$26.98M
Liabilities$87.82M
Net assets$114.83M
Liquid reserves1.5 mo
2 years on record · 2020–2022 · YoY revenue +8.2%
leadership · form 990 part vii · fy2022

who runs it

paid leadership · 16
NameTitleHours/wkCompensation
SALLY CAGLIOTI PRESIDENT/CEO 45 $936K
EUGENE ROBERTSON PHD VP, CHIEF OPERATING OFFICER 45 $635K
TANYA PERRY CHIEF FINANCIAL OFFICER 45 $582K
PHILIP WILLIAMSON PHD VP, CHIEF SCIENTIFIC OFFICER 45 $541K
Elizabeth Davis VP, Human Resources 45 $308K
Dustin Schodt VP, OPERATIONS (UNTIL 10/2022) 45 $283K
NANCY HAUBERT VP, PLASMA TESTING OPERATIONS 45 $281K
Sheryl Cyrus Director, Operations 45 $281K
SUBHASH PARAMESWARAN SR DIR, INFORMATION TECHNOLOGY 45 $272K
JANE HIPPISLEY DIRECTOR OF OPERATIONS II 45 $266K
AUDREY LOVE DIRECTOR OF OPERATIONS II 45 $256K
Leilani Palmer VP, Operations 45 $255K
Daniel Houghton Director, Operations 45 $250K
Chad Westhoven VP, Quality 45 $231K
BHAVI SHAH GENERAL COUNSEL/ASST SECRETARY 8 $184K
JEFFREY MODELL CHIEF INFORMATION OFFICER 45 $75K
board members · 9
  • ALLAN GOLDBERG — DIRECTOR
  • BRIAN HAMIL — DIRECTOR/CHAIR
  • CHRIS HROUDA — DIRECTOR
  • CRAIG MENDELSOHN — DIRECTOR
  • DAVID GREEN — DIRECTOR
  • GEORGE SCHOLL — DIRECTOR
  • KATHLEEN S PUSHOR — DIRECTOR
  • KATHY WALDMAN — DIRECTOR
  • NORMA SUTTON — DIRECTOR/SECRETARY-TREASURER
relationships · 17

who they work with

  • American Red Cross Partner — Owner organization and source of board members
  • Bloodworks Northwest Partner — Collaborates with CTS in the CTS Research Consortium to support infectious disease research.
  • Carter BloodCare Partner — Collaborates with CTS in the CTS Research Consortium to support infectious disease research.
  • FDA Government — Regulatory body with which CTS complies and responds to guidance changes, including EUA updates and withdrawal of ZIKV testing requirements.
  • Food and Drug Administration Government — Regulatory body for which CTS conducts required infectious disease marker and screening tests on blood and plasma donations.
  • Grifols Partner — Partner organization with which CTS assumed operations of three testing facilities on April 1, 2022.
  • IPFA Network — CTS is a member organization of IPFA, an organization dedicated to the safety of the world’s blood and plasma supply.
  • IPFA/PEI Partner — Participated in the IPFA/PEI 31st International Workshop in Heidelberg, Germany.
  • ITxM Partner — Collaborates with CTS in the CTS Research Consortium to support infectious disease research.
  • International Society of Blood Transfusion (ISBT) Partner — Collaborates with ISBT's Big Data Working Party to advance data availability in transfusion medicine.
  • New York Blood Center Partner — Collaborates with CTS in the CTS Research Consortium to support infectious disease research.
  • OneBlood Partner — Collaborates with CTS in the CTS Research Consortium to support infectious disease research.
  • OneBlood Partner — Owner organization and source of board members
  • Vitalant Partner — Owner organization and source of board members
  • Vitalant Research Institute Partner — Collaborates with CTS in the CTS Research Consortium to support infectious disease research.
  • healthcare partners Partner — Collaborates with healthcare partners on clinical trials and research studies.
  • over 100 healthcare entities Partner — Healthcare partners with whom CTS collaborates to provide laboratory testing services.